dpp-4 inhibitors vs. glp-1 agonist Insights into the Roles of GLP-1, DPP-4, and SGLT2 at the Crossroads of Cardiovascular, Renal, and Metabolic Pathophysiology It's the first in a
Description
Nausea, vomiting, dyspepsia, or abdominal distension in those taking GLP-1 agonists predict increased residual gastric contents
Therefore, considering the direct role of GIP and GLP-1 in adipose tissue, this effect on adipose tissue may also be beneficial in NAFLD
[DOI] [PubMed] [Google Scholar] 105.Al Jobori H., Daniele G., Adams J., Cersosimo E., Triplitt C., DeFronzo R.A., Abdul-Ghani M

15 they also reduce body weight by activating GLP1R in the central nervous system and suppressing appetite
